U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30N6O4S
Molecular Weight 474.5783
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILDENAFIL

SMILES

CCCc1c2c(c(=O)[nH]c(-c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4)n2)n(C)n1

InChI

InChIKey=BNRNXUUZRGQAQC-UHFFFAOYSA-N
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)

HIDE SMILES / InChI

Molecular Formula C22H30N6O4S
Molecular Weight 474.5783
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic guanosine monophosphate and smooth muscle relaxation.

CNS Activity

Curator's Comment:: CNS activity was observed on rats.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.5 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VIAGRA

Approved Use

VIAGRA is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.

Launch Date

8.9095681E11
Primary
REVATIO

Approved Use

REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.

Launch Date

1.11775685E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
159 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
530 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.07 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Disc. AE: Flushing, Headache...
AEs leading to
discontinuation/dose reduction:
Flushing
Headache
Tachycardia (mild)
Sources: Page: p.2
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Disc. AE: Visual field defect...
AEs leading to
discontinuation/dose reduction:
Visual field defect
Sources: Page: p.2
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources: Page: p.258
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 45
Sex: M
Population Size: 1
Sources: Page: p.258
Disc. AE: Rhabdomyolysis, Visual disturbance NOS...
AEs leading to
discontinuation/dose reduction:
Rhabdomyolysis
Visual disturbance NOS
Sources: Page: p.258
80 mg 3 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources: Page: p.1278
unhealthy, 47.5
n = 135
Health Status: unhealthy
Condition: Pulmonary arterial hypertension
Age Group: 47.5
Sex: M+F
Population Size: 135
Sources: Page: p.1278
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Disc. AE: Vomiting, Blurred vision...
AEs leading to
discontinuation/dose reduction:
Vomiting (severe)
Blurred vision
Sinus tachycardia
Sources: Page: p.1
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources:
Disc. AE: Cardiomegaly, Fibrosis myocardial...
AEs leading to
discontinuation/dose reduction:
Cardiomegaly (grade 5)
Fibrosis myocardial (grade 5)
Sources:
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (0.32%)
Vomiting (0.32%)
Leg pain (0.32%)
Backache (0.32%)
Intermittent headache (0.32%)
Dyspepsia (0.32%)
Headache (0.32%)
Sources: Page: p.1400
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1403
unhealthy, 60
n = 163
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 163
Sources: Page: p.1403
Disc. AE: Headache, Flushing...
AEs leading to
discontinuation/dose reduction:
Headache (0.61%)
Flushing (0.61%)
Sources: Page: p.1403
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Disc. AE: Headache, Flushing...
AEs leading to
discontinuation/dose reduction:
Headache (0.9%)
Flushing (0.44%)
Blurred vision (0.44%)
Groin pain (1.3%)
Sources: Page: p.1401
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.1,2
unhealthy, 67
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 67
Sex: M
Population Size: 1
Sources: Page: p.1,2
Disc. AE: Acute kidney injury...
AEs leading to
discontinuation/dose reduction:
Acute kidney injury
Sources: Page: p.1,2
AEs

AEs

AESignificanceDosePopulation
Flushing Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Headache Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Tachycardia mild
Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Visual field defect Disc. AE
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Rhabdomyolysis Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources: Page: p.258
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 45
Sex: M
Population Size: 1
Sources: Page: p.258
Visual disturbance NOS Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources: Page: p.258
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 45
Sex: M
Population Size: 1
Sources: Page: p.258
Blurred vision Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Sinus tachycardia Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Vomiting severe
Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Cardiomegaly grade 5
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources:
Fibrosis myocardial grade 5
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources:
Backache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Dyspepsia 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Headache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Intermittent headache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Leg pain 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Nausea 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Vomiting 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Flushing 0.61%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1403
unhealthy, 60
n = 163
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 163
Sources: Page: p.1403
Headache 0.61%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1403
unhealthy, 60
n = 163
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 163
Sources: Page: p.1403
Blurred vision 0.44%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Flushing 0.44%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Headache 0.9%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Groin pain 1.3%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Acute kidney injury Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.1,2
unhealthy, 67
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 67
Sex: M
Population Size: 1
Sources: Page: p.1,2
PubMed

PubMed

TitleDatePubMed
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.
2001
Use of sildenafil in penile implant patients.
2001
'Viagra effect' - influence of mass media on patient behavior.
2001
Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy.
2001 Apr
Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil.
2001 Apr
Intracavernosal injection of sildenafil citrate: misapplication of the drug.
2001 Apr
Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction.
2001 Feb
Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications.
2001 Feb
I've heard of an herbal alternative to Viagra for impotence. Does it work and is it safe?
2001 Feb
Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis.
2001 Feb
Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate.
2001 Feb
Interposition sural nerve grafting during radical retropubic prostatectomy.
2001 Feb
Sildenafil modulates hemodynamics and pulmonary gas exchange.
2001 Feb
Viagra for impotence of pulmonary vasodilator therapy?
2001 Feb
Should male patients with chest pain be questioned about Viagra use during triage screening?
2001 Feb
Sex and the heart: what is the role of the cardiologist?
2001 Feb
Are things looking up for the treatment of gastroparesis? Sildenafil in animal models of diabetic gastropathy.
2001 Feb
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
2001 Feb
[Endocrinology 1999-2000].
2001 Feb 15
Cost-effectiveness of sildenafil.
2001 Feb 6
Cost-effectiveness of sildenafil.
2001 Feb 6
Cost-effectiveness of sildenafil.
2001 Feb 6
The role of nitric oxide in penile erection.
2001 Jan
Sildenafil citrate: a therapeutic update.
2001 Jan
Intracavernosal injection therapy. Does it still have a role in erectile dysfunction?
2001 Jan
Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group.
2001 Jan
Sexual aspects of headache. How sexual function relates to headaches and their causes and treatment.
2001 Jan
pH-mediated field-amplified sample stacking of pharmaceutical cations in high-ionic strength samples.
2001 Jan
Viagra: are anaesthetists rising to the challenge?
2001 Jan
Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians.
2001 Jan
Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis.
2001 Jan
[Prescribing of sildenafil by national insurance program physicians. What basic sexual medicine qualification is required?].
2001 Jan 11
[Erectile dysfunction in coronary heart disease. No fear about the blue pill].
2001 Jan 18
[Paths to sexual satisfaction. What will stimulate the tired man?].
2001 Jan 18
Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries.
2001 Jan 26
Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site.
2001 Jan 26
Identification and regulation of human PDE5A gene promoter.
2001 Jan 26
[Drug treatment of erection disorders in patients with cardiovascular disease].
2001 Jan 27
Viagra: a three-year sexual revolution and the need to recognise its role within the NHS.
2001 Mar
Initial uptake in use of sildenafil in general practice.
2001 Mar
Anterior ischemic optic neuropathy associated with viagra.
2001 Mar
Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
2001 Mar
Sildenafil citrate and sperm function.
2001 Mar
Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium.
2001 Mar
In vivo and in vitro investigation of the effects of sildenafil on rat cavernous smooth muscle.
2001 Mar
Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats.
2001 Mar
Clinical efficacy of sildenafil in patients on chronic dialysis.
2001 Mar
Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England.
2001 Mar 17
Narrowbore high-performance liquid chromatography for the simultaneous determination of sildenafil and its metabolite UK-103,320 in human plasma using column switching.
2001 Mar 5
Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A.
2001 May
Patents

Sample Use Guides

Erectile disfunction: For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Pulmonary arterial hypertension: 5 mg or 20 mg three times a day, 46 hours apart (oral); 2.5 mg or 10 mg three times a day administered as an intravenous bolus injection.
Route of Administration: Other
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/20590607
Human bladder samples were treated with sildenafil (10 nM–30 µM) to test the ability of the drug to inhibit contraction.
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:33:35 UTC 2021
Edited
by admin
on Sat Jun 26 15:33:35 UTC 2021
Record UNII
3M7OB98Y7H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SILDENAFIL
EMA EPAR   HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
SILDENAFIL [VANDF]
Common Name English
SILDENAFIL RATIOPHARM
Brand Name English
APHRODIL
Brand Name English
HIP-0908
Code English
VIZARSIN
Brand Name English
PIPERAZINE, 1-((3-(6,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-4-ETHOXYPHENYL)SULFONYL)-4-METHYL-
Systematic Name English
SILDENAFIL [MI]
Common Name English
HIP0908
Code English
SILDENAFIL [EMA EPAR]
Common Name English
SILDENAFIL [WHO-DD]
Common Name English
SILDENAFIL ACTAVIS
Brand Name English
1-((3-(6,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-4-ETHOXYPHENYL)SULFONYL)-4-METHYLPIPERAZINE
Systematic Name English
SILDENAFIL [HSDB]
Common Name English
SILDENAFIL TEVA
Brand Name English
PATREX
Brand Name English
SILDENAFIL [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2127
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS VIZARSIN (AUTHORIZED: ERECTILE DYSFUNCTION)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS REVATIO (AUTHORIZED: HYPERTENSION, PULMONARY)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
WHO-VATC QG04BE03
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS VIAGRA (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
NDF-RT N0000175599
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
NDF-RT N0000020026
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS SILDENAFIL RATIOPHARM (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS PATREX (WITHDRAWN: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS SILDENAFIL ACTAVIS (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
FDA ORPHAN DRUG 344211
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS SILDENAFIL TEVA (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
WHO-ATC G04BE03
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EU-Orphan Drug EU/3/17/1885
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
LIVERTOX 885
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
Code System Code Type Description
WIKIPEDIA
SILDENAFIL
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
EVMPD
SUB10517MIG
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
NCI_THESAURUS
C61940
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
DRUG CENTRAL
2441
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
FDA UNII
3M7OB98Y7H
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
CAS
139755-83-2
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
RXCUI
136411
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL192
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
PUBCHEM
135398744
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
INN
7374
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
HSDB
7305
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
IUPHAR
4743
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
MESH
C101426
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
EPA CompTox
139755-83-2
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
MERCK INDEX
M9898
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY Merck Index
LACTMED
Sildenafil
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
DRUG BANK
DB00203
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY